We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current GILD market cap is 109.43B. The company's latest EPS is USD 4.5502 and P/E is 19.28.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 6.6B | 7.05B | 7.11B | 6.69B | 6.95B |
| Operating Income | 1.67B | 2.63B | 1.61B | -4.32B | 2.64B |
| Net Income | 1.05B | 2.18B | 1.43B | -4.17B | 1.61B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 22.45B | 24.69B | 27.31B | 27.28B | 27.12B |
| Operating Income | 4.29B | 4.07B | 9.92B | 7.33B | 7.61B |
| Net Income | 5.39B | 123M | 6.23B | 4.59B | 5.67B |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 62.34B | 62.37B | 62.13B | 56.29B | 53.58B |
| Total Liabilities | 41.24B | 40.13B | 39.38B | 38.84B | 35.38B |
| Total Equity | 21.09B | 22.24B | 22.75B | 17.46B | 18.2B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 61.63B | 68.41B | 67.95B | 63.17B | 62.13B |
| Total Liabilities | 38.98B | 50.19B | 46.89B | 41.96B | 39.38B |
| Total Equity | 22.65B | 18.22B | 21.06B | 21.21B | 22.75B |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 4.08B | 5.84B | 8.01B | 2.22B | 3.54B |
| Investing | -1.31B | -1.54B | -2.27B | -2.21B | -2.51B |
| Financing | -2.51B | -4.03B | -5.13B | -1.36B | -4.31B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 9.14B | 8.17B | 11.38B | 9.07B | 8.01B |
| Investing | -7.82B | -14.62B | -3.13B | -2.47B | -2.27B |
| Financing | -7.63B | 770M | -8.88B | -6.47B | -5.13B |
| Market Cap | 109.43B |
| Price to Earnings Ratio | 19.28 |
| Price to Sales Ratio | 4.03 |
| Price to Cash Ratio | 17.95 |
| Price to Book Ratio | 4.8 |
| Dividend Yield | 3.50% |
| Shares Outstanding | 1.24B |
| Average Volume (1 week) | 9.83M |
| Average Volume (1 Month) | 7.57M |
| 52 Week Change | 16.84% |
| 52 Week High | 98.90 |
| 52 Week Low | 62.07 |
| Spread (Intraday) | 0.45 (0.51%) |
| Company Name | Gilead Sciences Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.gilead.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
